2. Induced Disease Models Products Cell Cycle/DNA Damage
  3. Cancer Models DNA Alkylator/Crosslinker
  4. Gastric Cancer Models
  5. Methylnitronitrosoguanidine

Methylnitronitrosoguanidine  (Synonyms: MNNG)

Cat. No.: HY-128612 Purity: 99.96%
SDS COA Handling Instructions

Molarity Calculator

Methylnitronitrosoguanidine (MNNG) is an orally active alkylating agent with toxic and mutagenic effects. Methylnitronitrosoguanidine can as a carcinogen and mutagen. 50% water content, specifications are based on dry weight.

For research use only. We do not sell to patients.

Methylnitronitrosoguanidine Chemical Structure

Methylnitronitrosoguanidine Chemical Structure

CAS No. : 70-25-7

Size Price Stock Quantity
1 g USD 180 In-stock
5 g USD 450 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Methylnitronitrosoguanidine Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Methylnitronitrosoguanidine (MNNG) is an orally active alkylating agent with toxic and mutagenic effects. Methylnitronitrosoguanidine can as a carcinogen and mutagen[1][2]. 50% water content, specifications are based on dry weight.

In Vitro

Methylnitronitrosoguanidine (MNNG, 0-1100 nM; 24 h) has toxic and mutagenic effects among 3 human diploid lymphoblast lines, MIT-2, WI-L2, and GM 130[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Methylnitronitrosoguanidine Related Antibodies
In Vivo

Methylnitronitrosoguanidine (MNNG) is an alkylating agent that can be used to induce models of chronic atrophic gastritis and gastric cancer. In complete medium, the half-life of MNNG is approximately 70 minutes[3].

Induction of chronic atrophic gastritis[4]
Background
MNNG mainly simulates the transformation of nitrate into nitrosamine and other carcinogens in the stomach, which leads to chronic atrophic gastritis, dysplasia and even gastric carcinoma.
Specific Mmodeling Methods
Rat: Sprague-Dawley (SD) • male • 200 ~ 220 g (period: 10 weeks)
Administration: fed with pure water containing 170 μg/ml MNNG for 10 weeks
Note
(1) Pure water containing 170 μg/ml MNNG is stored in black bottles and refreshed every day since MNNG is not stable in solvent.
Modeling Indicators
Histopathological changes : Gastric mucosa pathological changes detected by HE staining.
Correlated Product(s): /
Opposite Product(s): HY-N0103

Induction of gastric carcinoma[5]
Background
MNNG is an alkylating agent, and its carcinogenicity is mainly due to its ability to covalently bond with the bases in DNA molecules to form alkylation products. This alkylation alters the way DNA is normally constructed and replicated, which leads to mutations in cells that can then develop into cancer.
Specific Mmodeling Methods
Rat: Wistar • male • 17w (period: 2 weeks)
Administration: 200 mg/kg • po • once daily for 2 weeks
Note
(1) Rats were given MNNG for 2 weeks followed by oral administration of NaCl (1 mL/rat) once every 3 days for 4 weeks.
(2) After 33 weeks, animals were allowed to fast and then were killed.
Modeling Indicators
Histopathological changes : Gastric mucosa pathological changes detected by HE staining.
Correlated Product(s): /
Opposite Product(s): /

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar albino rats[2]
Dosage: 200 mg/kg
Administration: Oral administration, at 0 and 14th days
Result: Had the incidence of gastric cancer in Wistar albino rats is 100%.
Molecular Weight

147.09

Formula

C2H5N5O3
CAS No.
Appearance

Solid-Liquid Mixture

Color

Light yellow to yellow

SMILES

N=C(N[N+]([O-])=O)N(C)N=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (849.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.7986 mL 33.9928 mL 67.9856 mL
5 mM 1.3597 mL 6.7986 mL 13.5971 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (14.14 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (14.14 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.96%

SDS (623 KB)

COA (245 KB) HNMR (213 KB) RP-HPLC (260 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 6.7986 mL 33.9928 mL 67.9856 mL 169.9640 mL
5 mM 1.3597 mL 6.7986 mL 13.5971 mL 33.9928 mL
10 mM 0.6799 mL 3.3993 mL 6.7986 mL 16.9964 mL
15 mM 0.4532 mL 2.2662 mL 4.5324 mL 11.3309 mL
20 mM 0.3399 mL 1.6996 mL 3.3993 mL 8.4982 mL
25 mM 0.2719 mL 1.3597 mL 2.7194 mL 6.7986 mL
30 mM 0.2266 mL 1.1331 mL 2.2662 mL 5.6655 mL
40 mM 0.1700 mL 0.8498 mL 1.6996 mL 4.2491 mL
50 mM 0.1360 mL 0.6799 mL 1.3597 mL 3.3993 mL
60 mM 0.1133 mL 0.5665 mL 1.1331 mL 2.8327 mL
80 mM 0.0850 mL 0.4249 mL 0.8498 mL 2.1245 mL
100 mM 0.0680 mL 0.3399 mL 0.6799 mL 1.6996 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Methylnitronitrosoguanidine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Methylnitronitrosoguanidine70-25-7MNNGDNA Alkylator/CrosslinkertoxicmutageniccarcinogenmutagenInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Methylnitronitrosoguanidine
Cat. No.:
HY-128612
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (623 KB) Français - FR (623 KB) Deutsch - DE (623 KB) Norwegian - NO (623 KB) Español - ES (623 KB) Swedish - SV (623 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.